Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a sell rating in a research note released on Saturday.

Several other equities research analysts have also recently issued reports on TVRD. Piper Sandler cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 8th. Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the stock an “equal weight” rating in a report on Monday, October 13th. Raymond James Financial lowered shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Finally, BTIG Research decreased their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, October 13th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $55.50.

Tvardi Therapeutics Price Performance

Tvardi Therapeutics stock opened at $4.41 on Friday. Tvardi Therapeutics has a 1 year low of $3.74 and a 1 year high of $43.65. The firm’s 50 day moving average price is $8.26 and its 200-day moving average price is $21.24. The stock has a market cap of $41.37 million, a P/E ratio of -0.46 and a beta of 0.11.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Trading of Tvardi Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of TVRD. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics during the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth about $43,000. Headlands Technologies LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $80,000. New York State Common Retirement Fund bought a new position in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Finally, Squarepoint Ops LLC bought a new position in Tvardi Therapeutics during the 3rd quarter valued at about $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.